Drugs / Varlitinib
Varlitinib
also known as
ASLAN001 · ARRY 334543 · AR-00334543 · AR00334543 ARRY-334543 ARRY-543 · Ar00334543 ditosilate · AR00334543 DITOSYLATE · Arry-334543 ditosilate · ARRY-334543 DITOSYLATE · +5 more
Small molecule targets EGFR, ERBB2 via inhibition
Trials 21
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT03368846 | Nov → Dec 2017 | — | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03082053 | Jan → Dec 2017 | biliary tract cancer | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02648425 | Aug 2014 → Jun 2017 | neoplasm | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02435927 | Aug 2014 → Jun 2021 | cancer | National Cancer Centre, Singapore | Unknown | No outcome recorded |
| Phase 1 | NCT00833326 | Jan 2009 → Jul 2010 | cancer of unknown primary site | Array BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT00710736 | Jun 2008 → Apr 2011 | cancer of unknown primary site | Array BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT00637702 | Feb 2008 → Oct 2012 | cancer of unknown primary site | Array BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT00278902 | Jan 2006 → Jun 2009 | cancer of unknown primary site | Array BioPharma | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05400915 | Jul 2019 → Dec 2021 | gastric cancer | Yonsei University | Completed | No outcome recorded |
| Phase 1/2 | NCT03499626 | May 2017 → May 2019 | hepatocellular carcinoma | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 1/2 | NCT02992340 | Dec 2016 → Jun 2020 | biliary tract cancer | ASLAN Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/2 | NCT02396108 | Mar 2015 → Mar 2018 | breast cancer | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 1/2 | NCT00862524 | Mar 2009 → Feb 2011 | cancer of unknown primary site, malignant pancreatic neoplasm | Array BioPharma | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT03129074 | May 2018 → Mar 2020 | biliary tract cancer | ASLAN Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03231176 | Dec 2017 → Jul 2019 | biliary tract cancer | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT07166367 | Aug 2016 → Jan 2020 | HER2 positive breast carcinoma | National Cancer Centre, Singapore | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02609958 | Nov 2015 → Jul 2017 | cholangiocarcinoma | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02338245 | Dec 2014 → May 2016 | breast cancer | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01614522 | Mar 2012 → Mar 2013 | gastric cancer | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03130790 | Aug 2017 → Dec 2018 | gastric cancer | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT03093870 | Jul 2017 → Nov 2019 | biliary tract cancer | ASLAN Pharmaceuticals | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-02-15 | Hyundai Pharmaceutical Co., LTD. | Results 현대약품, 'ASLAN001' 2상 임상 '긍정적 효과' 입증 hyundaipharm.co.kr ↗
현대약품(대표이사 김영학)이 신약개발사 아슬란과 공동투자하고 있는 '아슬란001(ASLAN001, 성분명 바리티닙)'이 2상 임상 연구에서 긍정적인 효과를 입증했다. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-02-15 | Hyundai Pharmaceutical Co., LTD. | 현대약품, 'ASLAN001' 2상 임상 '긍정적 효과' 입증 hyundaipharm.co.kr ↗ |
| 2016-07-08 | Hyundai Pharmaceutical Co., LTD. | 현대약품 공동개발 'ASLAN001', 美 FDA 위암 희귀의약품 지정 hyundaipharm.co.kr ↗ |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | varlitinib | “Varlitinib will be administered orally to the study participants at doses 300mg, BID in combination with the weekly intravenous infusion of Paclitaxel for 3 weeks with a rest...” NCT05400915 ↗ |
| Known as | AR-00334543 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103842 ↗ |
| Known as | AR00334543 ARRY-334543 ARRY-543 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103842 ↗ |
| Known as | Ar00334543 ditosilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103842 ↗ |
| Known as | AR00334543 DITOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103842 ↗ |
| Known as | ARRY 334543 | “Phase II Open Label Study to Evaluate the Biological Activity of ASLAN001 (ARRY 334543) in Patients With Recurrent/Metastatic Gastric, Gastro-oesophageal Junction, and...” NCT01614522 ↗ |
| Known as | Arry-334543 ditosilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103842 ↗ |
| Known as | ARRY-334543 DITOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103842 ↗ |
| Known as | ARRY-543 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103842 ↗ |
| Known as | Arry-543 ditosilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103842 ↗ |
| Known as | ARRY-543 DITOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103842 ↗ |
| Known as | ASLAN001 | “Varlitinib (also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive inhibitor of the tyrosine kinases - epidermal growth factor receptor (EGFR), human...” NCT03231176 ↗ |
| Known as | Varlitinib tosilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103842 ↗ |
| Known as | VARLITINIB TOSYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103842 ↗ |
| Action | Inhibit | “ARRY-334543, EGFR/ErbB2 inhibitor; oral” NCT00278902 ↗ |
| Modality | Small molecule | “ASLAN001 is a small molecule tyrosine kinase inhibitor against HER1, HER2, and HER4.” NCT02396108 ↗ |
| Route | Oral | “ARRY-334543, EGFR/ErbB2 inhibitor; oral” NCT00278902 ↗ |
| Target | EGFR | “ARRY-334543, EGFR/ErbB2 inhibitor; oral” NCT00278902 ↗ |
| Target | ERBB2 | “ARRY-334543, EGFR/ErbB2 inhibitor; oral” NCT00278902 ↗ |